Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology

Bio-Techne invites you to join them for an educational webinar.

Event Details:Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and ToxicologyDate(s):

Evaluating New 3-D Systems for Disease Modeling, Drug Discovery, and Toxicology from thescientistllc on Vimeo.

Cell and tissue-based models are a necessary step in the workflow for toxicology testing, drug discovery, and disease modeling. In recent years, the research and pharmaceutical industries have adopted more-complex ex vivo and in vitro 3-D tissue models because of their better predictive power. In this webinar, representatives from Bio-Techne will discuss the history of cell- and tissue-based model systems for toxicology, drug screening, and disease modeling. They also introduce MimEX™ Tissue Model Systems, a transformative culturing platform that builds upon the physiological and structural advancements of current organoid models by producing 3-D tissue with better accessibility and lower variability. Tune in to learn more about MimEX 3-D Tissue.

Topics to be covered:

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development